Mo-Rez in First- Line (1L) Maintenance Treatment of Non-Homologous Recombination Deficient Ovarian Cancer (Non-HRd OC) [BEHOLD-Ovarian03]

This study specifically aims to evaluate how well mocertatug rezetecan (Mo-Rez) alone or in combination with bevacizumab works in treating ovarian cancer compared to bevacizumab alone or active observation (AO). The study also assesses whether Mo-Rez is safe and tolerated well by participants in comparison to bevacizumab alone OR AO and will help provide a better understanding of the main side effects of the drugs.

Trial Details

NCT ID
NCT07694427
Phase
PHASE3
Sponsor
GlaxoSmithKline
Status
RECRUITING
Cancer Type
Ovarian Cancer
Interventions
  • Mocertatug rezetecan
  • Bevacizumab
Locations (sample)
  • Buenos Aires, Argentina|-34.61315,-58.37723
  • CABA, Argentina
  • Ciudad Autonoma de Buenos Aire, Argentina
  • Ciudad Autonoma de Buenos Aire, Argentina
  • Viedma, Argentina|-40.81519,-63.0004

Key Eligibility Criteria

  • Participants are eligible to be included in the study only if all of the following criteria apply:
  • Is at least 18 years of age and the legal age of consent in the jurisdiction in which the study is taking place at the time of signing the Informed…
  • Has newly diagnosed Stage III/IV (2014 FIGO staging) \[Berek, 2021\] epithelial ovarian, primary peritoneal or fallopian tube cancer with a histolo…
  • Has completed first-line platinum-based chemotherapy cycles. Inclusion of IV regimens at Q3W cycles, consolidation regimens and Intravenous (IV)/ I…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Ovarian Cancer Trials on Trialify →